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ABSTRACT: Current approved medical treatments for osteoporosis reduce fracture risk to a greater degree
than predicted from change in BMD in women with postmenopausal osteoporosis. We hypothesize that bone
active agents improve bone strength in osteoporotic bone by altering different material properties of the
bone. Eighteen-month-old female Fischer rats were ovariectomized (OVX) or sham-operated and left un-
treated for 60 days to induce osteopenia before they were treated with single doses of either risedronate
(500 mg/kg, IV), zoledronic acid (100 mg/kg, IV), raloxifene (2 mg/kg, PO, three times per week), hPTH(1-34)
(25 mg/kg, SC, three times per week), or vehicle (NS; 1 ml/kg, three times per week). Groups of animals were
killed after days 60 and 180 of treatment, and either the proximal tibial metaphysis or lumbar vertebral body
were studied. Bone volume and architecture were assessed by mCT and histomorphometry. Measurements of
bone quality included the degree of bone mineralization (DBM), localized elastic modulus, bone turnover by
histomorphometry, compression testing of the LVB, and three-point bending testing of the femur. The
trabecular bone volume, DBM, elastic modulus, and compressive bone strength were all signiﬁcantly lower at
day 60 post-OVX (pretreatment, day 0 study) than at baseline. After 60 days of all of the bone active
treatments, bone mass and material measurements agent were restored. However, after 180 days of treat-
ment, the OVX + PTH group further increased BV/TV (+30% from day 60, p < 0.05 within group and
between groups). In addition, after 180 days of treatment, there was more highly mineralized cortical and
trabecular bone and increased cortical bone size and whole bone strength in OVX + PTH compared with
other OVX + antiresorptives. Treatment of estrogen-deﬁcient aged rats with either antiresorptive agents or
PTH rapidly improved many aspects of bone quality including microarchitecture, bone mineralization,
turnover, and bone strength. However, prolonged treatment for 180 days with PTH resulted in additional
gains in bone quality and bone strength, suggesting that the maximal gains in bone strength in cortical and
trabecular bone sites may require a longer treatment period with PTH.
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INTRODUCTION
O
STEOPOROSIS IS A disease that results from the deteri-
oration of the material properties of such that the
bone fractures with very little stress. Osteoporosis is com-
mon in elderly postmenopausal women, and statistically,
nearly 50% of white women >50 yr of age will have an
osteoporotic fracture in their lifetime.
(1) Estrogen deﬁ-
ciency and aging-associated osteoporosis is referred to as a
disease of bone remodeling, as increased bone turnover
results in a reduction in bone mass, bone structure, and
localized intrinsic properties of the bone including the
degree of mineralization and bone strength. Currently, two
types of medications are approved for the treatment of
osteoporosis. These medications include antiresorptive
agents that reduce bone turnover and prolong the sec-
ondary mineralization phase of bone, which results in a
rapid improvement in bone strength because vertebral
fracture risk reduction is observed within 6 mo of initiating
the therapy.
(2,3) Bisphosphonates in general increase lum-
bar spine BMD ;3–4% after 1–2 yr of treatment.
(4,5)
PTH(1-34) is an anabolic agent; hPTH(1-34) has also
been approved for the treatment of osteoporosis and is
effective in improving bone strength and reducing verte-
bral and nonvertebral fracture risk in postmenopausal
women.
(6) Daily injections of hPTH(1-34) result in a rapid
increase in new bone formation followed by coupled bone
remodeling for the duration of the therapy.
(7) Trabecular
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209bone is the primary surface on which PTH initially changes
with increases in double labeled surface and thickness of
the trabeculae. Treatment of postmenopausal women with
PTH injections for 18 mo results in nearly 65% reduction
in new vertebral fractures and a gain in lumbar spine BMD
of nearly 9%.
(8) The improved bone strength after PTH
treatment is not associated with the gain in bone mass or
the magnitude of the bone turnover changes.
(8,9) Also,
because the initial effects of PTH are directed to the tra-
becular bone surface, less is known about the effect of PTH
on cortical bone. Anatomic sites with a high percentage of
cortical bone initially lose bone mass with PTH treatment
as a result of intracortical remodeling.
(10,11) However, PTH
stimulates bone formation more efﬁciently at active re-
modeling sites, and in aged female rats, estrogen deﬁciency
increases remodeling on the endocortical bone surface.
(12)
Cortical bone has a slower remodeling rate than trabecular
bone so any changes anticipated from PTH on cortical
bone would tend to be observed after sites rich in trabec-
ular bone, such as the lumbar spine.
(13) The association of
cortical bone mass changes and bone strength with PTH
has not been carefully evaluated.
To further evaluate the changes in the intrinsic properties
of bone that areinﬂuenced by estrogen deﬁciency, aging, and
osteoporosis treatment agents, investigators have initiated
studies that attempt to quantify the degree of bone miner-
alization and the distribution of the mineral across the bone
surface, the crystal size and orientation, and the material
properties of the bone surface by elastic modulus map-
ping.
(14–19) We hypothesized that aged osteopenic female
rats treated with either antiresorptive agents or an anabolic
agent, PTH, would gain bone mass and have changes in the
material properties of bone such that bone strength would
improve. We further hypothesized that prolonged treatment
with these agents would provide additional changes to the
material properties of the bone that might result in greater
bone strength. We found that short-term treatment with
both agents returned the bone mass and bone strength to
baseline levels. However, prolonged treatment with PTH
resulted in additional gains in both trabecular bone volume
and mineralization, in cortical bone mass, and in whole bone
and compressive strength compared with sham-operated
animals and animals treated with antiresorptive agents.
These observations suggest that prolonged treatment of os-
teoporotic women with PTH may have additional advan-
tages in bone strength through changes that occur in the
intrinsic properties of the bone matrix.
MATERIALS AND METHODS
Animals and experimental procedures
Female Fischer 344 rats were purchased from NIA
(Bethesda, MD, USA) and maintained on commercial
rodent chow (22/5 Rodent Diet; Teklad, Madison, WI,
USA) available ad libitum with 0.95% calcium and 0.67%
phosphate in a room that was maintained at 218C with a
12-h light/dark cycle. At 18 mo of age, the rats were ran-
domized by body weight into 15 experimental groups, and
animals were subjected to either sham surgery or ovariec-
tomy (OVX) (Table 1). The animals in groups 2–15 were
left untreated for 60 days to allow for the development of
trabecular osteopenia. At day 60 after OVX (day 0 of the
intervention study), groups 2 (pretreatment Sham control,
n = 6) and 3 (pretreatment OVX control, n = 6) were killed.
The other remaining animals were treated with either ve-
hicle (normal saline, SC, three times per week), risedronate
(Ris, 500 mg/kg, single IV injection at day 0), zoledronic
acid (Zol,100mg/kg,singleIVinjectionatday0),raloxifene
(Ral, 2 mg/kg, oral gauge, three times per week, days 0–
180), or hPTH(1-34) (25 mg/kg, SC, three times per week,
day 180; Table 1). The medication dosages used in this ex-
periment were derived from publications by the manufac-
turers that have been shown in osteopenic animals models
to be effective and similar in concentration to clinical
doses.
(20–23)Twenty-four-hoururinesampleswerecollected
every 60 days and were stored at –808C until they were used
to assessment of biochemical markers of bone turnover.
Xylenol orange (90 mg/kg) was given to all rats except
animals killed at baseline (day 260). All other animals
received calcein (10 mg/kg) followed by alizarin red
(20 mg/kg) subcutaneously at 14 and 4 days before death to
assess bone formation surface. At the time of death, the
right tibias were placed in 10% phosphate-buffered
formalin for 24 h and transferred to 70% ethanol for high-
resolution CT (mCT), bone histomorphometry, and scan-
ning probe microscopy (SPM). The fourth lumbar vertebral
bodies (LVB) were scanned by mCT, and the fourth LVB
and the left femurs were used for biomechanical testing.
All animals were treated according to the USDA animal
care guidelines with the approval of the UC Davis Com-
mittee on Animal Research.
Biochemical markers of bone turnover
Urinary levels of free deoxypyridinoline (DPD) cross-
links and osteocalcin were measured using an enzyme-
linked immunoassay (EIA) kit (DPD; Quidel; osteocalcin,
Biomedical Technologies, Stoughton, MA, USA). The
manufacturer’s protocols were followed, and all samples
were assayed in duplicate. A standard curve was generated
from each kit, and the absolute concentrations were ex-
trapolated from the standard curve. The CVs for interassay
and intra-assay measurements were <10% for all assays
and are similar to the manufacturer’s references. The DPD
TABLE 1. STUDY GROUPS AND EXPERIMENTAL DESIGN
Treatments
Days into study (age)
Day 260
(18 mo)
Day 0
(20 mo)
Day 60
(22 mo)
Day 180
(26 mo)
Sham + vehicle (Sham) G1 (6) G2 (6) G4 (6) G10 (7)
OVX + vehicle (OVX) G3 (6) G5 (6) G11 (9)
OVX + risedronate (Ris) G6 (9) G12 (9)
OVX + zoledronate
acid (Zol)
G7 (9) G13 (9)
OVX + raloxifene (Ral) G8 (10) G14 (10)
OVX + PTH (PTH) G9 (9) G15 (10)
Veh, vehicle; Ris, risedronate, 500 mg/kg, IV; Zol, zoledronate acid, 100
mg/kg, IV; Ral, raloxifene, 2 mg/kg, PO, 33/wk; G(#), groups and animal
numbers in each group.
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(24,25)
mCT measurements of the trabecular bone
microarchitecture and degree of
bone mineralization
The right proximal tibias (PTM) and the fourth lumbar
vertebral bodies (LVBs) were scanned with mCT (VivaCT
40; Scanco Medical, Bassersdorf, Switzerland) at an energy
level of 70 kev and intensity of 85 mA with an isotropic
resolution of 10.5 mm in all three spatial dimensions.
Scanning for the PTM was initiated proximally at the level
of growth plate and extended distally for 210 slices. Eval-
uations were performed on 100 slices beginning from ;0.2
mm distal to the growth plate. The entire LVB was scan-
ned, and the trabecular bone within the cranial and caudal
growth plates and the cortex was evaluated. The grayscale
images were segmented using a constrained 3D Gaussian
ﬁlter (sigma = 0.8, support = 1.0, a ﬁxed threshold of 240)
to extract the structure of mineralized tissue. Because
the scanner is self-calibrating before every scan, a ﬁxed
threshold provides the most reproducible result.
Trabecular bone volume (BV) was calculated using tet-
rahedrons corresponding to the enclosed volume of the
triangulated surface. Total volume was the volume of the
sample that was examined. A normalized index, BV/TV,
was used to compare samples of varying bone size. To
minimize the partial volume effects, two surface voxels
were discarded from every trabecula such that thick tra-
beculae (with 6 or more pixels) would be counted. The
methods used for calculating connectivity density, trabec-
ular number, and trabecular thickness have been described
previously.
(24,26,27) In addition, the attenuation coefﬁcient
(cm
21) of each pixel was calculated, and the histogram of
bone material concentration was derived for each animal
to calculate the mean degree of bone mineralization
(DBM) and mineralization distribution curve. The g HA/
cm
3 values were standardized with a manufacturer-
supplied phantom of ﬁve different HA densities embedded
in soft-tissue equivalent resin. Beam hardening effects
were corrected in the reconstruction process with a cor-
rection curve adapted to individual bone scans, as supplied
by the manufacturer. The degree of mineralization was
calculated from the whole bone sample region used for
architectural analyses.
(15,16) The average mineralization
(Ave-MIN) was deﬁned average mineralization of the
whole trabecular bone sample. Peak mineralization (Peak-
MIN) was deﬁned as the most frequent encountered min-
eralization obtained from the histogram of mineraliza-
tion.
(16) Low-MIN (%) was deﬁned as the percentage of
bone volume with mineral <0.8 g/cm
3, medium-MIN (%)
was deﬁned as the percentage of bone volume with mineral
0.8–1.2 g/cm
3, and high-MIN (%) was deﬁned as the per-
centage of bone volume with mineral >1.2 g/cm
3.
Measurement of elastic modulus by scanning
probe microscopy
After taking three 4-mm and one 8-mm sections for bone
histomorphometry, the remaining methylmethacrylate-
embedded proximal tibia blocks were further polished with
different diamond pastes starting from 10 mm down to 0.1
mm diameter to obtain smooth surfaces. We used a force
modulation technique called dynamic stiffness mapping
(DSM) to quantitatively map dynamic nanomechanical
properties with nanometer scale resolution.
(28) Modulus
maps in the form of scanning probe microscopy (SPM)
images were acquired using the direct-force modulation
operating mode of a TriboScope nanoindenter (Hysitron,
Minneapolis, MN, USA) mounted on a Multimode atomic
force microscope (AFM) controlled by NanoScope IIIa
electronics (Veeco, Santa Barbara, CA, USA). In this ex-
periment, the conventional AFM head was replaced by an
electrostatic operated transducer for simultaneous topo-
graphic and elastic modulus imaging. The topographic
contact mode was used ﬁrst to locate the area of interest,
usually 50 3 50 mm
2. Subsequently, the same area was
scanned in force modulation mode to record the elastic
modulus map. The amplitude of the modulated electro-
static force was set to 0.5–1.0 mN to maintain good signal-
to-noise ratio but was maintained sufﬁciently small to
prevent plastic deformation of the sample. Voigt and
Hertzian models were used to extract the elastic modulus
map of 256 3 256 pixels from the amplitude and phase of
displacements at each pixel.
(19) One representative PTM
was studied per group, with six different areas (images) on
each sample, and each area (or image) had 65,536 pixels.
We obtained statistics on 393,216 points for each sample.
The localized SPM distribution was plotted as the per-
centage of elastic modulus over the trabecular area studied
(Fig. 5A). A heterogeneity index of the surface elastic
modulus was adapted from the methods described by
Biovin and colleagues.
(14,29) It was deﬁned as the ‘‘full
width at half maximum’’ of the individual elastic modulus
mapping distribution curve across the trabecular surface.
The area underneath the curve was also calculated to
determine whether there were differences in the elastic
modulus between the experimental groups (Fig. 5B).
We assessed lacunar size and volume by two different
methods. The sizes of lacunae were estimated from the
polished sections of trabecular bone using the same dia-
mond tip used for the elastic modulus mapping. The lacu-
nae with the largest areas were located and assumed to
be the closest approximation to the mid–cross-section of a
3D ellipsoidal lacuna. These methods are similar to those
reported in our previous work.
(19)
Bone histomorphometry measurements of the tibial
trabecular and cortical bone
The right proximal tibial metaphyses (PTM) and the
shaft of the right tibia were dehydrated in ethanol and em-
bedded undecalciﬁed in methylmethacrylate. The PTMs
were sectioned longitudinally with a Leica/Jung 2255 mi-
crotome in 5- and 8-mm-thick sections. The 5-mm sections
were stained with tetrachrome stain for collection of bone
mass and architecture data with the light microscope,
whereas the 8-mm sections were left unstained for mea-
surement of ﬂuorochrome-based indices. The tibial shafts
were cut into 38-mm sections using a precision diamond
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The ﬁrst section proximal to the tibial–ﬁbula joint was se-
lected for evaluation. Bone histomorphometry was per-
formed using a semiautomatic image analysis Bioquant
system (Bioquant Image Analysis, Nashville, TN, USA)
linked to a microscope equipped with transmitted and
ﬂuorescent light.
Bone histomorphometric analyses were performed in
the secondary spongiosa of the right proximal tibias that
included trabecular area between 0.1 and 3 mm proximal
to the growth plate and within the cortex. Bone turnover
measurements included single- (sL.Pm) and double-
labeled perimeter (dL.Pm), interlabel width (Ir.L.Wi), and
osteoclast surface. These indices were used to calculate
mineralizing surface (MS/BS), mineral apposition rate
(MAR), bone formation rate (BFR/BS), and percentage
of osteoclast surface (Oc.S).
(24,25) Cortical bone measure-
ments included total cortical cross-sectional area (mm
2),
marrow area (%), and cortical bone thickness
(mm).
(19,24,25,30–32)
Biomechanical testing
The mechanical properties of the bone, speciﬁcally the
maximum compression and bending strengths, were de-
terminedusing both lumbarcompression tests onvertebrae
and three-point bending on un-notched femurs.
Biomechanical testing of the fourth lumbar vertebrae
(LVB) was performed using an axial compression test in
ambient air. The relevant cross-sectional dimensions and
the height of the specimens were measured using an optical
microscope with a 0.5-mm resolution (STM-UM Measuring
Microscope; Olympus American, Melville, NY, USA), af-
ter which they were subjected to unconﬁned compression
tests along the long axis of the lumbar vertebra with a
cross-head displacement rate of 0.01 mm/s. This test in-
volved loading the samples to failure while continuously
recording the corresponding loads and displacements.
Maximum load and the cross-sectional dimensions were
measured and used to determine the maximum compres-
sion strength.
(24,25)
The femora were received in 70% ethanol solution. The
ends of the femora were removed with a low-speed saw,
and the femora were placed in HBSS for at least 24 h be-
fore testing. To determine the bending strength of the
cortical bone, the femora were placed in an articulating,
three-point bending ﬁxture (with a lower-support loading
span of L = 15 mm). Specimens were placed onto the lower
support such that the bending axis corresponded with the
sagittal plane. The upper loading point was brought in
contact with the anterior side of the femur, and the speci-
men was loaded to failure in 378C HBSS at a displacement
rate of 0.01 mm/s using a servo-hydraulic materials testing
system (Model 831; MTS, Eden Prairie, MN, USA). The
applied force was measured with a calibrated load cell
(Sensotec Model 31), whereas the support travel was
measured with the system linear variable differential
transformer. After testing, a two-point average of the di-
ameter (anterior-posterior and medial-lateral) and a six-
point average of the thickness were measured at the
fracture site of each femur using digital calipers. Using the
average dimensions, the area moment of inertia was cal-
culated by approximating the cross-section as annular. The
maximum bending strength, smax, and the macroscopic
elastic modulus, E, were measured from the standard beam
bending equations in terms of the span length, L, the
maximum load, P:
smax ¼
PLc
4I
and E ¼
SL
3
48I
;
where c is the distance on the cross section from the
point of maximum tension to the neutral axis, I is the
moment of inertia of the circular cross section, and S is
the slope of the most linear region of the force versus
displacement data.
(11,33,34)
Statistical analysis
The group means and SDs were calculated for all out-
come variables. The nonparametric Kruskal-Wallis test
was used to determine differences at the same time point
with posthoc comparisons performed by Tukey’s test be-
tween groups at the same time point. (Version 12; SPSS,
Chicago, IL, USA). Differences were considered signiﬁ-
cant at p < 0.05.
RESULTS
Validation of the model
Estrogen deﬁciency induced trabecular bone loss and
increased bone turnover in the aged female rats at day 60
postovariectomy: Compared with the baseline group (day
60), there was no difference in BV/TV or bone turnover in
the sham-operated group at day 60 (day 0 of intervention
study). However, after 60 days of estrogen deﬁciency,
ovariectomized animals lost 33% trabecular bone mass at
the proximal tibia (Fig. 1) and 24% at the lumbar vertebrae
compared with the sham-operated animals at day 60 (p <
0.05). The majority of estrogen-deﬁcient trabecular bone
loss occurred during the ﬁrst 60 days postovariectomy. At
day 60, postovariectomy bone resorption, measured by
urine DPD cross-links (DPD/Cr), at the osteoclast surface
increased 2- to 3-fold. Also at day 60, postovariectomy,
bone formation measured by trabecular mineralizing
surface and surface-based bone formation rate increased
1- to 2-fold (Fig. 2; p < 0.05 compared with sham at the
same time point).
Intervention study (days 0–180)
Single intravenous doses of risedronate and zoledronic
acid and oral raloxifene restored trabecular bone mass,
whereas PTH(1-34) increased trabecular bone mass in aged
estrogen-deﬁcient rats: We used mCT to deﬁne the effects
of single intravenous doses of Ris and Zol, Ral, and
PTH(1-34) treatments on bone microarchitecture com-
pared with the vehicle-treated OVX animals. All anti-
resorptive agent, Ris, Zol, and Ral, treatments of OVX rats
signiﬁcantly increased bone volume (BV/TV) compared
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were 42%, 54%, and 55% greater than OVX + vehicle-
treated animals at day 60 (p < 0.05; Fig. 1), respectively,
and were similar to the sham-operated animals. At day
180, Ris, Zol, and Ral treatments of OVX animals further
increased BV/TV to 72%, 64%, and 65% greater than the
OVX + vehicle-treated animals at day 180, respectively
(p < 0.05; Fig. 1), and were all nearly 10% higher than the
sham-operated group (p < 0.05; Fig. 1). In contrast, after
60 days of treatment, PTH(1-34) BV/TV and trabecular
thickness (Tb.Th) increased by 80% and 31%, respectively,
compared with the OVX + vehicle-treated animals (p <
0.05; Fig. 1). At day 180, in PTH-treated animals, BV/TV
and Tb.Th were 150% and 40% greater than OVX +
vehicle-treated animals and were 63% and 32% greater
than the sham-operated group (p < 0.05; Fig. 1), respec-
tively. Also, PTH treatment resulted in BV/TV that was
signiﬁcantly greater than all other antiresorptive + OVX
treatment groups at day 180.
The PTHtreatmentgroup hadhigher total-cross sectional
area than the rest of the groups at day 180 (Figs. 3A–3C).
Endocortical area was higher in the OVX + vehicle and
OVX + Ral groups than the other groups at day 180 (Fig.
3D). Cortical bone thickness was 20% higher in the 60-day
FIG. 1. Proximal tibial trabecular bone microarchitecture changes measured by mCT. Mean values and SD for (A) trabecular bone
volume and (B) trabecular bone thickness from the right proximal tibial metaphyses obtained from groups of sham-operated (Sham) or
OVX animals treated with vehicle (OVX), risedronate (Ris), zoledronic acid (Zol), raloxifene (Ral), and PTH(1-34) from days 0 to 180.
ap < 0.05 vs. sham-operated animals at the same time point;
bp < 0.05 vs. OVX + vehicle-treated animals at the same time point.
FIG. 2. Serum biochemical
and surface based assessments
of bone turnover. Mean values
and SD for (A) urine DPD
(nmol) cross-links and creati-
nine (Cr, mmol) measured
by ELISA; (B) percent osteo-
clast surface (%); (C) percent
mineralizing surface (%); and
(D) percent surface-based bone
formation rate (mm/d). (B–D)
Measured from bone histo-
morphometry obtained from
the proximal tibial metaphysis
for groups of sham-operated
(Sham) or OVX animals trea-
ted with vehicle (OVX), ri-
sedronate (Ris), zoledronic
acid (Zol), raloxifene (Ral),
and PTH(1-34) (PTH) from
days 0 to 180.
ap < 0.05 vs.
sham-operated animals at the
same time point;
bp < 0.05 vs.
OVX + vehicle-treated animals
at the same time point.
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(+15%), OVX + Zol (+22%), and OVX + PTH(1-34)
(+37%) groups at day 180 compared with the OVX +
vehicle group (p < 0.05; Fig. 3E).
Antiresorptive treatments decreased, whereas PTH(1-34)
increased, bone turnover compared with the ovariectomized
animals: Compared with the OVX + vehicle-treated ani-
mals, OVX animals treated with single intravenous doses
of Ris or Zol and oral Ral had nearly a 50% reduction in
urine DPD/Cr and osteoclast surface so that the levels were
similar to the sham-operated levels at both day 60 and day
180 of the treatment period (p < 0.05). OVX + PTH(1-34)
treatment had a 59% increase in urine DPD/Cr levels at
day 60 and was similar to the OVX + vehicle group but
further increased at day 180 to 158% greater than the
sham-operated group (p < 0.05; Fig. 2). The OVX + PTH
group had similar OcS/B.S values as the OVX + vehicle
group at day 60 and day 180, but OcS/B.S. was 141%
greater at day 60 and 251% greater at day 180 compared
with the sham-operated group (p < 0.05; Fig. 2).
Bone formation rates measured by bone histomorpho-
metric analysis of trabecular bone in the proximal tibial
metaphysis indicated that OVX rats treated with either Zol
or Ral had similar mineralized surfaces and bone formation
rates/BS at days 60–180 compared with the sham-operated
rats. In contrast, OVX + Ris animals had signiﬁcantly de-
creased bone formation parameters (p < 0.05) compared
with sham and OVX + vehicle-treated groups (p <0 . 0 5 ;F i g .
2). Treatment with OVX + PTH(1-34) signiﬁcantly in-
creased mineralizing surface and bone formation rate/BS by
nearly 100% at day 60 compared with the sham-operated
animals and were similar to OVX + vehicle animals. At day
180, for the OVX + PTH group, these parameters were in-
creased by 43% and 86% compared with the vehicle-treated
animals and150% greater thanthe sham-operatedanimals (p
< 0.05; Fig. 2). Interestingly, double-labeled osteocyte surface
was assessed in the trabecular bone sections and was similar
at day 60 for OVX + vehicle and sham-operated animals (two
of total trabecular region) but was signiﬁcantly higher in the
OVX + PTH group (eight of total trabecular region) (data
not shown). However, by day 180, there was no double-la-
beled osteocyte surface observed in any experimental group.
Antiresorptive treatment restored the lost trabecular de-
gree of bone materialization after OVX, whereas PTH(1-
34) increased the degree of bone mineralization: We next
determined how single intravenous doses of either Ris or
Zol and long-term oral Ral treatments in old OVX osteo-
penic rats affected the degree of bone mineralization.
High-resolution mCT of the LVB and PTM was used to
determine the degree and DBM. Because trends for DBM
changes with all interventions were similar for the two
trabecular anatomic sites (PTM and LVB), we describe
here the results for the LVB. The Ave-MIN and Peak-MIN
in OVX + vehicle-treated animals did not differ signiﬁ-
cantly from the sham-operated group at days 60 and 180
(Fig. 4A; Table 2). Compared with all other groups, the
distribution of the DBM from OVX + vehicle-treated an-
imals was shifted to the left, especially at day 60, because of
a greater volume of bone with a higher percentage of lower
mineral values (14% and 8%, respectively, higher than
sham at days 60 and 180; Fig. 4A; Table 2). OVX + Ris or
Zol groups had similar Ave-MIN, Peak-MIN, and DBM
distribution as the sham-operated animals at day 60
(Fig. 4A; Table 2). At day 180, OVX + Ris or Zol groups
had higher Ave-MIN and Peak-MIN and a higher per-
centage of high-MIN than the OVX + vehicle group
(Fig. 4A; Table 2). The changes with OVX + Ral were
between the OVX + vehicle and sham + vehicle groups.
OVX + PTH(1-34)–treated animals had Ave-MIN, Peak-
MIN, and mineralization distribution at day 60 that was
similar to the OVX + vehicle-treated animals. However,
Ave and Peak-MIN were ;7% and 9% higher by day 180
FIG. 3. Tibial shaft cortical
bone histomorphometry. Un-
stained cross-sections of the
midtibial shafts from (A) day
60 and (B) day 180 animals
treated with vehicle, vehicle
(OVX), risedronate (Ris), zo-
ledronic acid (Zol), raloxifene
(Ral), and PTH(1-34) (PTH).
Note the enlarged marrow
cavities in OVX and Ral
groups at day 180 and the
markedly reduced marrow
cavities in Ris, Zol, and PTH
groups at day 180. At day 60,
Zol and PTH had higher in-
tracortical remodeling (labeled
osteon) in the inner third of the
cortex. PTH increased total
cross-sectional area and de-
creasedendocorticalareaatday
180 (C). (D) Treatment with
PTH increased the cortical
thickness at both days 60 and
180, whereas with Ris and Zol
increased cortical thickness at
day 180 (E).
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Fig. 3 live 4/Ccompared with the OVX + vehicle group (Fig. 4A; Table
2), which was similar to the OVX + Ris or Zol groups. The
distribution of mineralization at day 180 in the OVX +
PTH(1-34) group was shifted to the right, because of a
greater volume of bone with higher mineral concentration,
which was similar to the OVX + Ris or Zol groups.
Antiresorptive treatment restored, whereas PTH(1-34)
increased, localized and whole bone strength in osteopenic
ovariectomized rats: Mechanical compression testing of the
fourth lumbar vertebrae indicated that OVX + vehicle
resulted in a signiﬁcant reduction in compression strength
(Fig. 4B) and stiffness (data not shown) compared with
those in the sham-operated groups at days 60 and 180 (p <
0.05; Fig. 5). The maximum compression strength was
;70% higher in the Ris, Zol, and Ral + OVX treatment
groups compared with the OVX + vehicle-treated animals
at day 180 (p < 0.05), which was similar to the sham-
operated animals. The OVX + PTH group had 114%
higher compression strength compared with the OVX +
vehicle-treated group at day 180 (p < 0.05) and were
TABLE 2. DEGREE OF BONE MINERALIZATION OF THE VERTEBRAL TRABECULAR BONE
Treatment groups Ave-MIN (g/cm
3) Peak-MIN (g/cm
3) Low-MIN (%) Medium-MIN (%) High-MIN (%)
D60
Sham 0.89 ± 0.04 1.03 ± 0.01 12.9 ± 1.4 69.9 ± 4.6 17.2 ± 0.6
OVX 0.88 ± 0.05 0.98 ± 0.03 30.8 ± 2.1* 66.5 ± 2.7 2.7 ± 0.1*
Ris 0.95 ± 0.03 1.07 ± 0.04 17.7 ± 1.9 64.4 ± 4.4 17.9 ± 1.9
†
Zol 0.90 ± 0.04 1.05 ± 0.03 15.0 ± 1.9
† 69.5 ± 7.5 15.5 ± 3.1
†
Ral 0.93 ± 0.05 0.99 ± 0.04 21.7 ± 2.2* 68.2 ± 4.2 10.1 ± 0.5*
†
PTH 0.93 ± 0.05 1.03 ± 0.03 19.5 ± 2.1* 67.9 ± 4.5 12.6 ± 4.7
†
D180
Sham 0.89 ± 0.03 1.01 ± 0.03 13.9 ± 2.0 68.8 ± 4.5 17.3 ± 0.6
OVX 0.87 ± 0.03 0.93 ± 0.05 17.7 ± 2.1* 66.5 ± 4.2 15.9 ± 0.3*
Ris 0.97 ± 0.04*
† 1.14 ± 0.04*
† 12.8 ± 2.0 56.1 ± 4.4 31.9 ± 1.9
†
Zol 0.95 ± 0.03*
† 1.11 ± 0.04
† 14.7 ± 2.2
† 60.7 ± 2.4 24.5 ± 2.1
†
Ral 0.88 ± 0.02 0.94 ± 0.03 28.7 ± 2.8* 67.6 ± 1.4 3.7 ± 0.5*
†
PTH 0.94 ± 0.03
† 1.10 ± 0.04*
† 7.5 ± 2.5
† 59.9 ± 3.5 32.6 ± 5.7
†
Please refer to the Materials and Methods section for deﬁnitions of Ave-MIN and Peak-MIN and percentages for Low-, Medium-, and High-MIN.
* p < 0.05 from sham.
† p < 0.05 from OVX at the same time point.
FIG. 4. (A) Degree of bone mineralization (DBM) and mineral distribution generated by high-resolution mCT for trabecular bone of
the fourth lumbar vertebral bodies at days 60 and 180. The distribution of mineralization shifted to the left with OVX at day 60, with
lower values of DBM. All the treatment groups had similar trabecular mineral distribution curves as the sham controls at day 60. At day
180, Ris, Zol, and PTH treatment shifted the mineral distribution to the right, with more bone of higher mineral concentration. (B)
Lumbar vertebral compression strength and femoral maximum bending strength at days 60 and 180. At day 60, antiresorptive treatments
and PTH had similar lumbar compression strength that was signiﬁcantly higher than the OVX group. At day 180, PTH further increased
lumbar compression strength, which was higher than all the other groups. Femoral bending strengths were increased with Ris and PTH
treatments compared with the OVX at day 180.
ap < 0.05 vs. sham at the same time point;
bp < 0.05 vs. OVX at the same time point;
cp <
0.05 vs. the antiresorptive groups.
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It should be noted that the compression strength of the
vertebrae is signiﬁcantly lower than the bending strength of
the femurs; this is most likely associated with the much
higher fraction of trabecular bone in the vertebrae.
With respect to the maximum bending strength of the
cortical bone, three-point bending testing of the femurs in-
dicated that OVX + vehicle resulted in a signiﬁcant reduc-
tion in strength compared with those in sham-operated
groups at day 180 (p < 0.05; Fig. 4B). The bending strength
was ;18% higher in the Ris + OVX treatment groups
compared with the OVX + vehicle-treated animals at day
180 (p < 0.05), which was similar to the sham-operated an-
imals.OVX+PTHgroupshad42%higherbendingstrength
compared with the OVX + vehicle-treated group at day 180
(p < 0.05) but was not signiﬁcantly higher than the sham-
operated group.
Localized elastic modulus values of the PTM trabecular
surface measured at day 180 showed that OVX + vehicle
induced a signiﬁcant reduction in elastic modulus (stiff-
ness) together with increased the heterogeneity (Fig. 5).
The OVX + Ris, Zol, or Ral and sham groups all displayed
similar elastic moduli and had a greater percentage of high
elastic modulus values compared with OVX + PTH. The
heterogeneity index of antiresorptive treatments and PTH
was similar to that of sham (Fig. 5). However, PTH had the
highest overall elastic modulus compared with all other
groups at 180 days (p < 0.05). In addition, osteocyte lacu-
nae size, measured from the SPM, found that the average
size of nearly 50 osteocyte per treatment group was lower
in PTH-treated animals than OVX + vehicle and OVX+
antiresorptive agents (mean ± SD: 40.1 ± 7.5 mm
2 versus
OVX + vehicle [68.7 ± 15.5 mm
2] versus OVX + anti-
resorptive agents [59 ± 10.7 mm
2]).
DISCUSSION
The determinants of bone fragility in osteoporosis and
how currently approved treatments for osteoporosis aug-
ment bone strength independent of changes in BMD are
still beingdeﬁned.
(35–37) Therefore, weevaluatedtheeffects
of antiresorptive agents and PTH on other properties of
bone quality including bone microarchitecture, surface-
based and biochemical markers of turnover, mineralization,
crystal size, and whole bone material properties in aged
estrogen deﬁciency OVX rats for 60 and 180 days. We
found that treatment of osteopenic aged rats with either
antiresorptive agents or PTH restored bone mass, total
trabecular and cortical mineralization, and strength after
60 days, with turnover reduced with antiresorptive agents
and increased with PTH. However, from day 60 to day 180,
the PTH-treated group had additional gains in bone mass,
bone mineral concentration, and trabecular and cortical
bone strength. Our data suggested that over time PTH
treatment may be superior to antiresorptive agents and that
it may have a greater inﬂuence on cortical bone strength.
In clinical medicine, antiresorptive agents and PTH are
prescribed for individuals with low bone mass or osteo-
porotic fractures and both seem to reduce the risk of
new incident vertebral fractures by a similar magni-
tude
(4,5,38–44); however, risedronate seems to have a more
rapid action, with signiﬁcant vertebral fracture reduction
after 6 mo of therapy.
(3) The bone strengthening properties
of bisphosphonates result from a reduction in the initiation
of bone remodeling. This allows for a prolongation of the
secondary mineralization phase and more total bone min-
eral, a lower ratio of low to highly mineralized bone, and a
more uniform distribution of mineral, which are all asso-
ciated with improved bone strength.
(14–16,29,45–48) Our work
and that of others have reported that the degree of min-
eralization in trabecular bone is a strong predictor of bone
strength. The majority of preclinical studies based on short-
term intervention studies of 2–3 mo report an increased
degree of bone mineralization seems to be advantageous to
bonestrength.However,theclinicaluseofthesemedications
is for many years. Although long-term use of oral bis-
phosphonates seems to maintain bone strength over 10 yr,
it is not clear if the change in bone mass or degree of bone
mineralization is associated with the maintenance of this
improved bone strength.
(49)
Another aspect of bone strength is the rate of bone
remodeling, which results in the release of mineral and
FIG. 5. Localized elastic mo-
dulus of the PTM trabecular
surface measured at day 180.
OVX + vehicle induced a sig-
niﬁcant reduction in elastic
modulus and increased the
heterogeneity. OVX + Ris,
Zol, or Ral and sham had sim-
ilar elastic modulus, which had
a greater percentage of high
elastic modulus compared with
OVX + PTH. The heterogene-
ity index of antiresorptive
treatments and PTH was simi-
lar to that of sham. However,
PTH had the highest overall
Elastic modulus compared with
all the other groups at 180 days.
ap < 0.05 from all the other
groups.
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ing causes a removal and replacement of both the mineral
and unmineralized matrix. Estrogen deﬁciency uncouples
remodeling with increased osteoclast and osteoblast mat-
uration and activity.Biochemical markersof bone turnover
that are correlated with the uncoupling of bone remodeling
include TRACP 5b, urinary DPD, and serum osteocalcin.
In this study, treatment with antiresorptive agents reduced
remodeling rates and rapidly lowered biochemical markers
of bone turnover. This was conﬁrmed by surface-based
histomorphometry after treatment initiation and was
maintained throughout the treatment period. In contrast,
treatment with PTH increased bone turnover with in-
creased urine and serum markers of osteoclast maturation
and activity, osteoblast activity, and turnover by histo-
morphometry. Reduction in bone turnover over time with
antiresorptive agents inhibits the replacement of the bone
matrix. However, PTH stimulates remodeling and replaces
the matrix with divalent cross-links of collagen I, which is
characteristic of younger bone, whereas older bone has
more trivalent cross-links.
(50,51) Bone biopsies from
osteoporotic women treated with PTH and placebo for 18
mo had a lower ratio of trivalent to divalent cross-links.
(51)
Divalent cross-links are reported to decrease fracture load
and offset yield load; however, trivalent cross-links en-
hance bone toughness.
(52) Therefore, we hypothesize that
antiresorptive agents may increase the concentration of
trivalent cross-links in bone, thereby enhancing bone
toughness, whereas PTH may improve bone strength
by increasing divalent cross-links despite initially reducing
matrix mineralization and mineral crystallinity. Additional
studies that include multiple doses of both antiresorptive
agents and PTH are needed to test this proposed
hypothesis.
Because this experiment used aged female rats, we
studied the surface-based turnover at both the trabecular
and cortical bone sites and found evidence for both endo-
cortical and Haversian remodeling in the cortical bone of
these aged estrogen-deﬁcient rats. It is generally believed
that Haversian remodeling does not present in the rat
species. However, it can be induced under circumstances
such as after fatigue loading
(33) or thyroparathyroidec-
tomized
(53)-induced hypocalcemia. In this study, the ani-
mals were >18 mo old when the study was initiated and
nearly 30 mo at the termination of the study. Very few
studies, if any, have conducted extensive histological
analysis with this age of rat. Sixty days of PTH treatment
elevated double-labeled surfaces on the trabecular, endo-
cortical, and the peri-osteocyte lacunae surfaces in areas
adjacent to the remodeling sites. The double-labeled bone
around the osteocyte lacunae was present at both the
60- and 180-day time points. Other groups have reported
young osteocytes have PTH receptors and can form nod-
ules when exposed to PTH in vitro; Midura et al.
(54,55) re-
ported calcein labeling around osteocytes near the perios-
teum of rats treated with PTH. The signiﬁcance of PTH’s
ability to stimulate bone formation around the osteocyte is
not known. The size of the osteocyte lacunae of PTH-
treated animals was signiﬁcantly less than animals treated
with antiresorptive agents, vehicle-treated OVX animals,
and sham controls in this study. The osteocyte is respon-
sible for sensing the loads of the bone through the ﬂuid that
ﬂows through it. The extracellular matrix that surrounds
the osteocyte senses the load and transmits it through
SIBLING proteins to the osteocyte. Osteocyte lacunae size
is hypothesized to be associated with how effective the
bone is at absorbing shear force. Smaller osteocyte lacunae
may be better able to absorb shear forces than larger la-
cunae. Inability of the osteocyte to absorb shear force can
result in microcracks, possibly apoptosis, or signals sent to
the surface of the bone that initiate remodeling.
(56,57) In
previous reports, we showed that increased osteocyte la-
cunae size was associated with a loss of mineral sur-
rounding the osteocyte in glucocorticoid-treated mice
(19)
and reduced localized elastic modulus. Both acute and
prolonged estrogen deﬁciency is reported to induce apo-
ptosis of osteocytes in vivo,
(58–60) and both estrogen and
selective estrogen receptor modulators were able to inhibit
this effect in vitro.
(60,61) The OVX + vehicle-treated ani-
mals in this study were estrogen deﬁcient for nearly
240 days, and this group had larger osteocyte lacunae size
and increased Haversian remodeling in the cortex. Addi-
tional studies are needed to determine whether lacunae
size is related to apoptosis of the osteocytes with estrogen
deﬁciency and whether treatment with an antiresorptive
agent or PTH can alter localized bone strength related to
the changes in osteocyte and lacunae sizes.
After 60 days of PTH treatment, estrogen-deﬁcient an-
imals had improved bone mineralization of the trabecular
bone from the lumbar vertebrae compared with the OVX +
vehicle-treated group. However, by day 180, the PTH-
treated animals had a higher percentage of trabecular bone
with higher mineral that was similar to the animals treated
with bisphosphonates. PTH initially increases bone turno-
ver and cortical bone porosity,
(9,11) and we found that PTH
initially stimulated bone turnover, created a mineralization
lag,
(51,62) and increased cortical bone remodeling. How-
ever, at day 60, bone strength was similar in PTH- and
bisphosphonate-treated animals, suggesting that high
turnover in the presence of improved bone mass and mi-
croarchitecture was a more important determinant for
bone strength; PTH treatment from days 60 to 180 resulted
in nearly 30% greater bone mass with a shift toward more
highly mineralized bone in the trabecular bone regions,
ﬁlling in of the intracortical bone remodeling spaces, and
an increase in cortical bone thickness. The prolonged
treatment with PTH may have allowed for the new osteoid
to completely mineralize. The further increase in bone
mass and degree of mineralization further augmented bone
strength in both trabecular and cortical bone sites.
Localized material properties of trabecular bone can
provide additional information about overall bone quality.
Such measurements were made using a modulus mapping
technique, which permitted multiple measurements of the
elastic modulus or stiffness across the trabecular surface of
the bone. The elastic modulus that was measured is the so-
called Young’s modulus, which is a measure of the stiffness
of the bone (it is the tensile or compressive stress needed
for unit increase in elastic deformation). The scanning
probe–based modulus mapping technique is particularly
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stiffness of small entities such as trabeculae.
Previous experiments of glucocorticoid treatment and
estrogen deﬁciency showed a reduced local elastic modulus
at the trabecular bone surface and within the trabecular
around the osteocyte lacunae; this reduced stiffness in
glucocorticoid-treated mice bone was associated with re-
duced bone mineral to matrix ratio assessed by Raman
spectroscopy.
(19,34) In this study, 240 days of estrogen de-
ﬁciency was associated with a higher percentage of tra-
becular surface with lower elastic modulus compared with
antiresorptives and PTH. PTH treatment produced an
overall increase in surface elastic modulus with similar
distribution of elastic modulus, as observed with the sham-
operated and antiresorptive treatment groups. The extent
in which the localized changes contribute to overall bone
strength is not clear. It has been suggested that nonuniform
inelastic deformation over large surface areas increased
energy dissipation over a uniform material.
(63) The heter-
ogeneity of the localized elastic modulus distribution over
the trabecular bone surface may inhibit crack propagation
or failure in the bone. However, this concept requires ad-
ditional experiments.
Trabecular bone strength measured by compression of
the lumbar trabeculae found that, after 60 days of either
antiresorptive agents or PTH, the bone strength had all
increased to the sham level. Antiresorptive agents can
rapidly improve bone strength through reduction in re-
modeling and increasing bone mineralization.
(15,20,29) How-
ever, PTH treatment may rapidly increase bone strength
by changing the trabecular bone microarchitecture in-
cluding trabecular thickness and connectivity. By day 180,
PTH treatment lumbar vertebral compression strength
was greater than that in the sham-treated animals. The
additional gain in bone strength with prolonged PTH
treatment may be that this additional treatment time al-
lowed the osteoid to fully mineralize the bone matrix.
Prolonged PTH treatment also improved cortical bone
strength, which may be the result of a combination of
Haversian remodeling cycle completion and increased
cortical bone thickness resulting from endocortical and
periosteal bone formation. Recently, 20-wk-old estrogen-
replete mice treated for 7 wk had gains in vertebral bone
mass between 10% and 13% with alendronate and 14%
and 33% with PTH. The combination of the two treat-
ments in both daily and cyclic regimens may be more
beneﬁcial than either treatment alone in improving bone
quality.
(64)
In summary, treatment of estrogen-deﬁcient aged rats
with either antiresorptive agents or PTH rapidly improved
many aspects of bone quality including microarchitecture,
bone mineralization, turnover, and bone strength. How-
ever, prolonged treatment for 180 days with PTH resulted
in additional gains in bone quality and bone strength sug-
gesting that the maximal gains in bone strength in cortical
and trabecular bone sites may require a longer duration of
PTH treatment. Other studies that evaluate the role of
dose-response of these agents on bone quality will help
to further reﬁne our observations and translate this pre-
clinical observation to practice.
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